Investigational mAbs targeting various surface markers in AML, such as CD123, CD45, CLL1, TIM3, CD47, and CD70, have shown promise, necessitating further exploration and optimization [23,24]. The gene discussed is CD47; the disease is acute myeloid leukemia.